Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;291(6):886-890.
doi: 10.1111/joim.13449. Epub 2022 Jan 10.

Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure?

Noemi Pavo  1 , Suriya Prausmüller  1 , Georg Spinka  1 , Georg Goliasch  1 , Philipp E Bartko  1 , Henrike Arfsten  1 , Karine Santos  2 , Guido Strunk  3 , Martin Hülsmann  1
Affiliations

Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure?

Noemi Pavo et al. J Intern Med. 2022 Jun.
No abstract available

Keywords: angiotensin; angiotensin-receptor-neprilysin-inhibition (ARNI); heart failure; renin; renin-angiotensin system (RAS).

PubMed Disclaimer

Conflict of interest statement

KS is an employee of 4TEEN4 Pharmaceuticals GmbH. 4TEEN4 Pharmaceuticals GmbH holds the patent rights on the DPP3 biomarker and humanized antibody Procizumab. cDPP3 measurements were sponsored by 4TEEN4 Pharmaceuticals and were carried out in a blinded fashion. Matching of patient data to cDPP3 was performed by NP.

Figures

Fig 1
Fig 1
cDPP3 in advanced HFrEF. (A) Distribution of cDDP3 in advanced stable HFrEF, (B) association of cDDP3 with HF etiology and (B) RAS‐inhibitor therapy, (C) relationship between cDPP3 and neurohumoral derangement and (D) association of cDPP3 and outcome. For (C) scatter plots, linear regression lines and Spearman's Rho correlation coefficients with the level of significance are shown for the correlation between cDPP3 and NT‐proBNP, renin, norepinephrine, GDF‐15, bio‐ADM, Copeptin, big‐ET‐1, PENK and plasma NEP activity. For (D) Cubic spline curves are shown for the combined endpoint of all‐cause mortality and unplanned HF hospitalizations as well as for the endpoints separately. Distribution of cDPP3 levels with quartiles are displayed in the graphs. Hazard ratios (HR) and the 95% confidence intervals are shown for each curve.
See this image and copyright information in PMC

References

    1. Deniau B, Rehfeld L, Santos K, Dienelt A, Azibani F, Sadoune M, et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur J Heart Fail. 2020;22:290‐299. - PubMed
    1. Takagi K, Blet A, Levy B, Deniau B, Azibani F, Feliot E, et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur J Heart Fail. 2020;22:279‐286. - PubMed
    1. Boorsma EM, Ter Maaten JM, Damman K, van Veldhuisen DJ, Dickstein K, Anker SD, et al. Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure. Eur J Heart Fail. 2021. - PMC - PubMed
    1. Zelniker TA, Spaich S, Stiepak J, Steger F, Katus HA, Preusch MR. Serum neprilysin and the risk of death in patients with out‐of‐hospital cardiac arrest of non‐traumatic origin. Eur Heart J Acute Cardiovasc Care. 2020;9:S169‐S174. - PubMed
    1. Butler J, Braunwald E, Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA. 2014;312:789‐90. - PubMed